Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised ...
New Protocol: Isatuximab – carfilzomib – dexamethasone for relapsed/refractory multiple myeloma - Altai Oncology
Combination of Isatuximab, Carfilzomib, and Dexamethasone Reduces Risk of Disease Progression in Myeloma - The ASCO Post
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial - The Lancet
Dosing and Administration | KYPROLIS® (carfilzomib)
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design | Future Oncology
Treatment With Carfilzomib: A Promising Future for Multiple Myeloma - JADPRO
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma - ScienceDirect
Cancers | Free Full-Text | Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomat
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study - ScienceDirect
Dosing and Administration | KYPROLIS® (carfilzomib)
Addition of Daratumumab Increases Benefit of Carfilzomib/Dexamethasone in Multiple Myeloma - The ASCO Post
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i ...
Modified low-dose carfilzomib plus dexamethasone treatment protocol... | Download Scientific Diagram
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma | Blood Cancer Journal
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial - The Lancet
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
